TECH · 8-K · 20260923PR037450

Acquisition / Partnership / Divestiture

BIO-TECHNE Corp · 2026-09-23 · Importance 71 · Surprise 60

Bio-Techne shareholders approved and adopted the definitive agreement for Merck KGaA, Darmstadt, Germany to acquire the company at a special meeting on September 23, 2026. The release describes the transaction as delivering substantial near-term cash value to Bio-Techne shareholders but does not disclose the consideration amount. The Hart-Scott-Rodino waiting period expired at 11:59 p.m. Eastern Time on September 18, 2026. Bio-Techne expects the transaction to close by late 2026 or early 2027, subject to customary closing conditions, including remaining required regulatory approvals.

Key facts

• Bio-Techne expects the transaction to close by late 2026 or early 2027, subject to customary closing conditions, including receipt of remaining required regulatory approvals. source
• Bio-Techne shareholders approved and adopted the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne at a Special Meeting of Shareholders held September 23, 2026. source
• The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired at 11:59 p.m. Eastern Time on September 18, 2026, in connection with the proposed transaction. source
• The final voting results, as certified by the independent inspector of elections, will be reported in a Form 8-K filed with the SEC. source
• Restrictions during the pendency of the proposed transaction may impact Bio-Techne’s ability to pursue certain business opportunities or strategic transactions. source
• Bio-Techne identified the possibility that revenues following the proposed transaction may be lower than expected. source
• Bio-Techne identified the possibility that operating costs, customer loss, and business disruption—including difficulties maintaining relationships with employees, customers, clients, or suppliers—may be greater than expected following the proposed transaction. source
• Bio-Techne identified retention of certain key employees as a risk associated with the proposed transaction. source